What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Neuroendocrine Tumor Research Foundation

Home
United States
Boston, MA
Neuroendocrine Tumor Research Foundation

Dedicated to discovering better treatments and cures for patients with neuroendocrine cancers. Leading global funder of neuroendocrine cancer research.

03/19/2026

You're invited to our Community Fundraising Webinar on March 25!

If you’ve ever thought about organizing a fundraiser to raise vital funds for neuroendocrine cancer research, we're here to help you get started.

Join our Community Fundraising Webinar on March 25 at 2 p.m. (ET).

We’ll share simple ideas, practical tools, and ways that NETRF can support you every step of the way.

To register, please contact Steve Perna at steve.perna@netrf.org

03/16/2026

We're thrilled to announce Chiara Mazziotta, PhD, Research Fellow at Dana-Farber Cancer Institute, as a recipient of a NETRF Mentored Research Award! 🎉

Dr. Mazziotta's research focuses on Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine skin cancer. Her work centers on two proteins, YAP and TAZ, that are inactive in MCC cells. Interestingly, when reactivated in the lab, these proteins cause MCC cells to stop growing and die.

She's also studying the role of the mTOR pathway in helping MCC cells survive. Her findings point to a new dual strategy to block mTOR while reactivating YAP and TAZ. These insights have potential implications for other neuroendocrine cancers as well.

Learn more about Dr. Mazziotta’s project: https://ow.ly/SbKH50YuXkW

Special thanks to Elaine Nord for making this promising research possible. 🔬

03/12/2026

🎉Congratulations to Suzann Duan, PhD, Assistant Professor at UC Irvine, on her NETRF Investigator Award for research exploring how aging impacts gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Dr. Duan’s team aims to identify age-related signals that reprogram the gut’s support cells, called glial cells, potentially leading to new biomarkers for earlier detection and treatments targeting aging-related pathways, including some with existing FDA-approved drugs.

Read more about Dr. Duan’s research: https://ow.ly/uRbb50Yt6z6

NETRF is proud to support Dr. Duan as she works to advance new treatments and ultimately cures for neuroendocrine cancer.

-NETs

03/10/2026

Why do some pancreatic neuroendocrine tumors (PanNETs) resist treatment?

NETRF Mentored Research Award recipient Yeonghwan Kim, PhD, Postdoctoral Fellow at Columbia University, is working hard to answer that question.

🔬Dr. Kim’s team discovered that a protein called VEGF-C may help tumors bypass therapies that cut off their blood supply. This research expands possibilities for more personalized treatments that could slow tumor growth, reduce liver metastases, and improve survival and quality of life for patients.

Read more about this novel research: https://ow.ly/ywJs50YrPeG

This is the kind of bold, innovative science that offers new hope for patients with PanNETs and their loved ones.👏

03/06/2026

A few hours remain to take our annual patient and caregiver survey before it closes at midnight ET tonight!

Don't miss the chance to share your input to inform the programming for Know Your NETs 2026.

Take the survey now ➡️ https://ow.ly/7JoB50YqtNR

03/05/2026

🎉 We are proud to congratulate Kirsten Kübler, MD, PhD, Professor at the Berlin Institute of Health at Charité, on her NETRF Pilot award.

Some pancreatic neuroendocrine neoplasms (NENs) undergo a process called metaplasia, where tumors become more aggressive and less responsive to treatment over time. This makes predicting how these tumors will respond to treatment especially challenging. Dr. Kübler's team will conduct detailed molecular studies of these tumors to identify biomarkers that can flag when this transformation is occurring.

A deeper understanding of this process could lead to targeted therapies and improved outcomes for patients with pancreatic NENs.

Read more about Dr. Kübler’s research ➡️ https://ow.ly/xZH750YpH1F

Research like this is at the core of NETRF’s mission, to improve outcomes and offer hope to patients and their loved ones.

03/03/2026

Can blocking a single protein change the course of treatment for neuroendocrine cancer patients? That's the question driving the work of one of this year's NETRF Pilot Award recipients, Thomas Walter, MD, PhD, Professor at Cancer Research Center of Lyon.

Dr. Walter's research centers on two proteins, MTAP and PRMT5, that play key roles in cancer cell survival. His team will analyze tumor samples to understand how levels of these proteins vary across different neuroendocrine tumors, and will test PRMT5-blocking drugs in the lab.

If successful, this work could identify an entirely new class of treatments for NET patients and help determine which patients are most likely to benefit.

Read more about Dr. Walter’s research: ➡️ https://netrf.org/research/prmt5-inhibitor-next-option-for-neuroendocrine-tumors/

Congratulations to Dr. Walter and profound thanks to the Family and Friends of Diamond Brown for making this research possible.

02/28/2026

Why is neuroendocrine cancer on the rise?

NETWise Episode 52 explores some possible answers. Listen now ➡️ https://ow.ly/O8H050Yngsz

Recent studies have shown that neuroendocrine cancer diagnoses have increased sharply over the past twenty years, but what's behind the rise in incidence?

In this episode of NETWise, leading clinicians, researchers, and a patient explore what’s driving the rise in neuroendocrine cancer diagnoses and what it means for patients today. From advances in imaging and pathology to the growing number of tumors discovered incidentally, this conversation reveals how earlier detection is reshaping care, research, and outcomes.

This episode brings clarity to the rising numbers and what that progress means for patients, caregivers, and clinicians.

Be sure to listen and share this latest episode and follow NETWise wherever you get your podcasts.

02/27/2026

🎉 We're thrilled to congratulate NETRF Pilot Award winner Tiane Chen, MD, PhD, MSc, Assistant Professor at Johns Hopkins University!

Dr. Chen's research investigates GLP-1R, a protein that may serve as a powerful biomarker for pancreatic neuroendocrine tumors (PanNETs). Weight-loss and diabetes drugs like Ozempic and Wegovy are GLP-1 receptor agonists. Understanding their impact on neuroendocrine tumors is important, given the widespread use of these medications. By analyzing a large cohort of patient cases, her team aims to determine whether GLP-1R expression is linked to tumor aggressiveness and the likelihood of recurrence or metastasis.

This work has the potential to unlock more personalized treatment strategies and new discoveries that improve survival rates and quality of life for this patient population.

Read more about Dr. Chen’s project ➡️ https://ow.ly/tHcF50Yne7I

We’re grateful for the opportunity to support this promising science.

02/20/2026

🔦We're excited to spotlight Yuanyuan Qiao, PhD, Research Assistant Professor at the University of Michigan, a recipient of a 2025 Investigator Award for her work to discover more effective treatments for gastroenteropancreatic NETs (GEP-NETs).

Dr. Qiao's lab is investigating how GEP-NETs rely on fats and cholesterol to fuel their growth. By blocking a protein called PIKfyve, particularly in combination with the standard mTOR inhibitor everolimus, her team seeks to disrupt both fat metabolism and iron balance within tumor cells, making them significantly more vulnerable to treatment.

This work could lead to therapies for GEP-NETs that are not only more powerful but also longer-lasting.

Read more about this novel study: https://ow.ly/Jv8050Yii9a

Congratulations to Dr. Qiao for her work to drive new discoveries and therapies for GEP-NET patients.👏

-NETs

02/19/2026

🎉Congratulations to Craig Levin, PhD, Professor at Stanford University and a recipient of a 2025 NETRF Investigator Award for his research to innovate Positron Emission Tomography (PET) scans for neuroendocrine cancer!

Currently, PET scanners can only use one tracer per scan, meaning patients may need multiple scans to get a full picture of their disease. Dr. Levin's team is developing a method to run two tracers (FDG and 68Ga-DOTATATE) simultaneously in a single PET scan, delivering complementary data on NET metabolism and somatostatin receptor expression all at once.

This has the potential to reduce patient burden, improve diagnostics, and offer better guidance to inform treatment decisions.

Read more about Dr. Levin’s project ➡️ https://ow.ly/xm2w50YifRa

Here’s to research that aims to improve patient experience and outcomes at once.

https://www.facebook.com/stanfordmedicine

02/13/2026

🔬Meet Susanne Kossatz, PhD, a recipient of a 2025 NETRF Investigator Award for her research to improve care for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)!

Dr. Kossatz, based at TUM Klinikum Rechts der Isar in Munich, Germany, is working to strengthen peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

PRRT delivers targeted radiation to tumor cells, damaging their DNA to slow or stop growth. Some cancer cells can repair that damage and continue growing, which can lead to tumor progression. At the same time, radiation can negatively impact healthy tissue, resulting in side effects.

With this grant, Dr. Kossatz is pairing PRRT with a DNA repair–blocking drug to keep tumor cells from fixing the radiation damage, which could make treatment more effective and longer lasting. By delivering the drug directly to tumor cells, her approach also aims to limit exposure to healthy tissue and reduce side effects.

Early lab and animal studies are encouraging. If successful, this strategy could help patients receive more treatment cycles and achieve longer-lasting benefits.

Read more about Dr. Kossatz’s research ➡️ https://ow.ly/cmp950YfnTX

Special thanks to the Karpus Family Foundation for making this grant possible.

Address

100 Hancock Street
Boston, MA
02171

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+16179461780

Website

http://www.netrf.org/

Alerts

Be the first to know and let us send you an email when Neuroendocrine Tumor Research Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.